Victory laps in Ireland after Heartware and Diabetes

Quote

anonymous

Guest
"Chairman and CEO" Geoff Martha, fresh from taking his victory laps in Ireland, has NOTHING to say about the Heartware and Diabetes pump debacles, but has more than enough wokeness to go around. Mr "we're all about the patient" cuts corners and then goes quiet when caught with his hand in the cookie jar. #stonecoldloser
 
















Speaking at the 40th Annual J.P. Morgan Healthcare Conference today, Martha expressed his disappointment with the hitches in important businesses.

“I feel a mix of disappointment and anger,” Martha said. “And, I feel deeply accountable for this. … But, it’s important to reiterate that, while these programs are delayed, they are still expected to be meaningful growth drivers going forward.”

In October, the medtech giant announced that the clinical study of its Symplicity Spyral renal denervation (RDN) system for hypertension would continue into next year after lacking the positive results needed to end enrollment early. The following month, supply chain and manufacturing issues resulted in the announcement that Medtronic’s much-anticipated Hugo surgical robot launch was off-schedule.

The third setback for Medtronic came last month when the company received an FDA warning letter focused on the inadequacy of specific medical device quality system requirements at its diabetes business’ Northridge, California, facility.
 




anonymous said:
Speaking at the 40th Annual J.P. Morgan Healthcare Conference today, Martha expressed his disappointment with the hitches in important businesses.

“I feel a mix of disappointment and anger,” Martha said. “And, I feel deeply accountable for this. … But, it’s important to reiterate that, while these programs are delayed, they are still expected to be meaningful growth drivers going forward.”

In October, the medtech giant announced that the clinical study of its Symplicity Spyral renal denervation (RDN) system for hypertension would continue into next year after lacking the positive results needed to end enrollment early. The following month, supply chain and manufacturing issues resulted in the announcement that Medtronic’s much-anticipated Hugo surgical robot launch was off-schedule.

The third setback for Medtronic came last month when the company received an FDA warning letter focused on the inadequacy of specific medical device quality system requirements at its diabetes business’ Northridge, California, facility.
Click to expand...

Geoff has decided the way to show he's in charge is to parade out all the new leaders he is bringing in, to show he's found the problem and its anyone who'se been here for a few years... Watch for more seasoned leaders to head for the doors as this fiscal year ends.... tired if being left holding the bag for a tough quarter.
 








Quality of Medtronic’s reputation was earned years ago. Quality of Medtronic’s execution and delivering on its age old reputation in recent years has been a dismal failure. Failure of leadership on multiple levels.
 




anonymous said:
Geoff has decided the way to show he's in charge is to parade out all the new leaders he is bringing in, to show he's found the problem and its anyone who'se been here for a few years... Watch for more seasoned leaders to head for the doors as this fiscal year ends.... tired if being left holding the bag for a tough quarter.
Click to expand...

Geoff's been here almost longer than anyone, since 2011 to be exact. Wait, maybe hes the problem?
 








Top Bottom
Back
Quote